

創業40年の医薬品製造事業





40

同社は、医薬品有効成分の製造を目的として、1982年にインドのパンジャブ州で設立されました。

同社は、医薬品原薬 (API) 製造会社であり、医薬品製造にこれらの製品を使用する製薬業界の大手企業数社のために原材料を製造しています。

ファイザー、アボット、シプラ、グレンマーク、マクラウド、アリストなどの企業に製品を供給しています。

同社は、抗生物質、ビタミン、抗凝固剤から眼科用製品まで、幅広い製品を提供しています。ビジネスは、ISO、ZED、インドおよび海外の規制当局による GMP などのいくつかの組織によって監査も受けています。

リサーチ

ビジネスは、新しい標的療法に効果があり、副作用のないことを保証する組換えタンパク質の特許技術に取り組んでいます。

現在、事業はハイエンドの新規分子に焦点を当てています。

研究

同社は現在、幹細胞若返り療法に関する実験研究を行っており、副作用のない医薬品の将来も約束されています。

バイオテクノロジー

同社は、標的ヒト治療用タンパク質の分野で重要なバイオテクノロジー研究活動に取り組んでいます。

現在の研究活動は、喘息やアレルギー患者を治療しながら、肥満細胞症や好塩基球性白血病にも効果を発揮する新規薬の開発に焦点を当てている。

チーム

チームは、化学者、薬剤師、バイオテクノロジスト、品質管理者、研究開発の専門家、倉庫担当者など、100人の賢明な個人で構成されています。

市場: 65% インド / 35% その他の世界 / ヨーロッパ

製品: 25 の OEM 製品 / 医薬品有効成分原料

TARGET PRICE

\$40,000,000

GROSS REVENUE

\$25,000,000

EBITDA

\$3,000,000

BUSINESS TYPE

製造業

ESTABLISHED

1989

SUPPORT & TRAINING

12ヶ月

REASON FOR SELLING

退職

COUNTRY

インド

BUSINESS ID

L#20210013

最も売れた商品: 抗生物質

規格: ISO9001、EU 規格 (FDA なし)

成長率: 20%+/年

規模: 従業員 100 人以上

管理者: 化学エンジニアの経歴

財務: 収益 2,500 万ドル / EBITDA 300 万ドル

お客様:

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM